































Bodybuilding DVD's
Ronnie Coleman
Colossal Workout
Dennis Wolf
Dorian Yates
Believe to Achieve
Jay Cutler's house
Hard and Heavy







|
Hepatoxicity: Fact or Fiction
We all know that the alpha alkylated steroids are hepatoxic, right….. But, is
there actually any truth to this? We’ve been told for years that if you take 17
alpha-alkylated steroids, you will eventually run into liver problems. Never
combine 17 aa’s, never go beyond 50mg day, never go longer than 4 weeks, etc.
All of this is crap! As I we walk you through some studies, today, you’ll see 17
alpha-alkylated steroids can be hepatoxic but not to the degree you would think.
To make a steroid hepatoxic, you need only a small change to a steroid molecule;
A strong bond that cannot readily be down broken by enzymes in the liver. This
may be a bond at the 17th position, or even at the 1st position (as in
methenolone or proviron). Because the liver cannot easily break the steroid down
before it is released in to the blood stream, this also results in the steroid
to becoming more orally bio-available.
We can see that the liver has to work harder to break down these steroids.
Enzymes in the blood and tissue easily metabolize other steroids such as
Testosterone. Commonly, this increase in liver activity has been viewed as a
harmful process, but as you will see, this increase is, in and of itself,
irrelevant. The liver is THE filter of the human body -- it can figure out what
to do with just about anything. The only real problem comes in when one keeps
their liver at full blast for long periods of time.
Let’s look at some studies showing the Hepatoxicity of steroids. Here's
one of my favorites, a study published in 1979[1]. Essentially, researches did a
study of deaths caused by hepatic angiosarcoma (a malignant tumor of vascular
tissue in the liver) between 1964 and 1974. Researchers found 131 reported cases
of death from hepatic angiosarcoma. Out of the 131 cases, 3.1% (4 cases) were
reported to be at all related to the use of androgenic-anabolic steroids. Keep
in mind that these 4 people could have liver complications before any steroids
were used, aka a genetic disposition. In fact there is no proof, in this study
at least, that the anabolic-androgenic steroids even caused the hepatic
angiosarcoma.
This is the classic case of associating a cause with an effect, without any
evidence, aside from both existing. Furthermore, based on the above numbers,
there are only 0.4 cases of hepatic angiosarcoma reported each year, by those
using AAS. Now consider the number of people on steroids at this time. Now
factor in all the people that don’t know their ass from a hole in the ground
when it comes to using AAS, properly. Clearly, this is very week evidence.
Lastly there has not been a real increase in hepatic angiosarcoma since the
early seventies. Meanwhile, there has been a huge, almost exponential, increase
in steroid use during this period.
Another study, that somewhat supports the previous Hepatoxicity case, showed the
possibilities of hepatic adenomas (cysts in the liver) caused by
androgenic-anabolic steroids[2]. In this study, a Japanese girl was found to
have multiple liver lesions after the use of the drug oxymetholone (aka
Anadrol). Most everyone “knows” that Anadrol is linked with liver problems, but
a closer inspection into this study shows more.
Apparently, this girl, starting at the age of 14, was diagnosed with aplastic
anemia. She was prescribed oxymetholone at 30mg per day. This continued for 6
years until the lesions first appeared. Assuming that the girl was most likely
around 100 lbs., this was a pretty heavy dosage. If you extrapolated this data
out to a 200 - 250lbs. male, that would be taking approximately 60 - 90mg of
anadrol per day for 6 years. Ouch!
The researchers also stated that there were only 17 other cases of hepatic
adenomas, found in English literature between 1975 and 1998. They failed to
mention the causes of these 17 cases, but there is no reason to believe they
were all using 17-AA androgens and 17 is certainly miniscule compared to the
number of people who have used them. The authors’ finish off the study by saying
the following: "This report may be helpful in identifying the population who is
at risk of developing hepatic sex hormone-related tumors." So remember, if
you're a small 14-year-old girl taking 30mg of Anadrol per day for 6 years, you
may be at risk!
Let's move on to some more useful studies. Take for example a 1995 study that
showed the toxic effects of anabolic-androgenic steroids in primary rat hepatic
cell cultures[3]. In this study the researchers used the following drugs and
dosages:
Steroid
*1x10^-8M
**1x10^-6M
***1x10^-4M
19-nortestosterone
0.002744mg*
0.2744mg**
27.44mg***
Fluoxymesterone
0.003365mg*
0.3365mg**
33.65mg***
Testosterone cypionate
0.004126mg*
0.4126mg**
41.26mg***
Stanozolol
0.003285mg*
0.3285mg**
32.85mg***
Danazol
N/A
N/A
N/A
Oxymetholone
0.003325mg*
0.3325mg**
33.25mg***
Testosterone
0.002884mg*
0.2884mg**
28.84mg***
Estradiol
0.0027424mg*
0.2724mg**
27.24mg***
Methyltestosterone
0.003024mg*
0.3024mg**
30.24mg***
As proof of the hepatoxicity they used Lactate dehydrogenase release, neutral
red retention, and glutathione depletion to determine plasma membrane damage,
cell viability, and possible oxidative injury, respectively.
What they showed was that the 17 alpha-alkylated steroids, methyltestosterone,
stanozolol and oxymetholone, significantly increased Lactate dehydrogenase
release and decreased neutral red retention at the 1x10^-4M dosage for 24h. Both
methyltestosterone and oxymetholone also showed depleted glutathione at the
1x10^-4M dosage after 2h, 6h and 8h treatments. In other words they increased
liver activity. You may also note that the other, non-alkylated steroids showed
no significant difference in any levels. All in all this not only shows that 17
alpha-alkylated steroids are directly “hepatoxic”, but also non-alkylated
steroids are note hepatoxic at all. But is this a real measure of hepatoxicity?
There is yet to be any correlation between the increase of the above-mentioned
measurement and “hepatoxicity”. Obviously, high dosages of the 17
alpha-alkylated steroids are potentially dangerous, but upon closer inspection,
the study reveals more.
Take a look, the researchers took cell cultures from the liversse of 60-day-old
Sprague-Dawley rats. Not only are rat livers much smaller than human livers, but
these were merely cultures. Furthermore, it was the 1x10^-4M concentrations that
caused the most changes, but these are approximately 1 to a 1/3 of a full, daily
human dosage -- at least for the 17 alpha-alkylated steroids. Even at the
1x10^-6M concentration, there were no significant changes observed. It's
apparent that the levels of 17 alpha-alkylated steroids used were potentially
toxic, but for a human to take the same amount would be insane. I'm guessing
this could translate to maybe 4 grams every 24 hours or 28 grams a week if not
more.
What is common so far is we can only prove that any steroid, that is believed to
be hepatoxic, only increases liver activity. I’ll say it again, where is the
correlation to hepatoxicity? We know that if the liver is running at 100% for
long periods this may cause complications, but this is akin to any other
chemical, which is metabolized by the liver. Ever noticed that liver cancer due
to alcoholism takes decades of constant alcohol abuse? It’s apparent that the
possibility for hepatoxicity is there, but for the smart steroid user this is
nearly an impossible task.
Another study done in 1999, attempted to show the acute and chronic effects of
stanozolol on the liver[4]. In acute treatments of stanozolol, dosages not
mentioned, both cytochrome P456 and b5 (microsomal enzymes) levels dropped after
48 hours, and then at 72 hours, levels significant increased. On the other hand,
with chronic treatments, time or dosage not mentioned, these microsomal enzymes
showed a decrease in levels. Researchers showed that both acute and chronic
treatments resulted in "slight to moderate inflammatory or degenerative lesions
in centrilobular hepatocytes", but the authors did not note true hepatotoxicity.
How about we look at the other side of the story, the good studies. For
instance, in a 1999 study, which looked at the effects of an 8-week cycle of 17
alpha-alkylated steroids[5]. The researchers used fluoxymesterone,
methylandrostanolone, or stanozolol on rats at 2mg/kg-body weight, five times a
week for 8 weeks. That's 182mg per dosage, for a 200lb man, or 910mg per week.
Half of the rats were sedentary and the other were trained on a treadmill.
Levels of NADH-cytochrome c reductase, succinate cytochrome c reductase, and
cytochrome oxidase (showing liver activity), increased in the
steroid-administered rats, while citrate synthase showed no change.
Comparatively, in vitro, the "cytochrome oxidase and citrate synthase activities
were insensitive to the AAS, whereas NADH-cytochrome c reductase and succinate
cytochrome c reductase activities were partly inhibited."
Furthermore, in vivo, each rat had liver enzyme levels that were within normal
range. From this, the researchers determined that the steroid-administered rats,
trained or sedentary, did not show "...classical serum indicators of hepatic
function". Extrapolating this, 910mg a week for 8 weeks could potentially have
little to no effect on the liver in humans.
As for human studies, in 1999 researchers tried to prove that the hepatoxicity
of steroids is overstated[6]. In this study, 15 of the participants were
bodybuilders using self-administered steroid dosages and 10 were non-steroid
bodybuilders. Serum data was compared to 49 patients with viral hepatitis, and
592 exercising and non-exercising medical students. [
All of the bodybuilders showed increases in aspartate aminotransferase (AST),
alanine aminotransferase (ALT) and creatine kinase (CK) while gamma-glutamyltranspeptidase
(GGT) levels were in the normal range. In comparison, hepatitis patients showed
increased ALT, AST, and GGT levels while the control exercising medical students
showed increased CK levels. From this, the researchers suggested that it is the
correlation between AST, ALT and GGT that shows true liver dysfunction. Keep in
mind, we can only guess that the 15 steroid users were using 17 alpha-alkylated
steroids, and we do not know what the dosages that were used., but common sense
tells us the results are likely relevant.
Last but not least, a simple study done in 1996, showed the long term benefits
after taking a 3 month break from steroids[7]. 16 bodybuilders using steroids
were compared to 12 bodybuilders that were not. After a three-month drug
withdrawal, the researchers showed that levels of liver enzymes, types not
mentioned, returned to the same as the non users. Again the dosages are left to
the reader’s imagination and we can only guess that the 16 steroid users were
using 17 alpha-alkylated steroids.
So what can we conclude from all of this? First off, 17 alpha-alkylated steroids
are hepatotoxic in high dosages taken for a long time. On the other hand, short
cycles and small dosages appear to be perfectly safe. I suggest that maximum
dosages should be 50mg to 90mg per day. They should be cycled for perhaps 8
weeks at a time, and if needed a 3-month break from them should be used. Using
the above-mentioned techniques, your liver can be healthy for a long time.
Simply put, the hysteria surrounding “hepatoxic” steroids, is based mainly on
folk lore.
References:
[1] Lancet 1979 Nov 24;2(8152):1120-3, Hepatic angiosarcoma associated with
androgenic-anabolic steroids. Falk H, Thomas LB, Popper H, Ishak KG.
[2] J Gastroenterol 2000;35(7):557-62, Multiple hepatic adenomas caused by
long-term administration of androgenic steroids for aplastic anemia in
association with familial adenomatous polyposis. Nakao A, Sakagami K, Nakata Y,
Komazawa K, Amimoto T, Nakashima K, Isozaki H, Takakura N, Tanaka N.
[3] J Pharmacol Toxicol Methods 1995 Aug;33(4):187-95, Toxic effects of
anabolic-androgenic steroids in primary rat hepatic cell cultures. Welder AA,
Robertson JW, Melchert RB.
[4] Arch Toxicol 1999 Nov;73(8-9):465-72, Evaluation of acute and chronic
hepatotoxic effects exerted by anabolic-androgenic steroid stanozolol in adult
male rats. Boada LD, Zumbado M, Torres S, Lopez A, Diaz-Chico BN, Cabrera JJ,
Luzardo OP.
[5] Med Sci Sports Exerc. 1999 Feb;31(2):243-50, Rat liver lysosomal and
mitochondrial activities are modified by anabolic-androgenic steroids. Molano F,
Saborido A, Delgado J, Moran M, Megias A.
[6] Clin J Sport Med 1999 Jan;9(1):34-9, Anabolic steroid-induced hepatotoxicity:
is it overstated? Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, McConathy
WJ.
[7] Int J Sports Med 1996 Aug;17(6):429-33, Body composition, cardiovascular
risk factors and liver function in long-term androgenic-anabolic steroids using
bodybuilders three months after drug withdrawal. Hartgens F, Kuipers H, Wijnen
JA, Keizer HA.
|
|